All In Biotech

Drug Trial Radar · NCT01803282

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

236

Actual

Start

Mar 29, 2013

Primary completion

Apr 23, 2019

Study completion Apr 23, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy. The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part. Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory to or intolerant to standard therapy or for which no standard therapy exists. In Part A, participants will receive andecaliximab only. Part B is a dose expansion to obtain additional safety and tolerability data for andecaliximab in participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part B, participants will receive andecaliximab in combination with standard-of-care chemotherapy.

Conditions

  • Pancreatic Cancer
  • Non-small Cell Lung Cancer
  • Esophagogastric Cancer
  • Colorectal Cancer
  • Breast Cancer

Interventions

  • AndecaliximabDrug

    Administered intravenous infusion

  • GemcitabineDrug

    Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

  • Nab-paclitaxelDrug

    Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

  • CarboplatinDrug

    Administered intravenously on Day 1 of each 21-day treatment cycle

  • PemetrexedDrug

    Administered intravenously on Day 1 of each 21-day treatment cycle

  • LeucovorinDrug

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • OxaliplatinDrug

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • 5-FUDrug

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • BevacizumabDrug

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • IrinotecanDrug

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • PaclitaxelDrug

    Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse EventsTime frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
  2. Percentage of Participants Experiencing Laboratory AbnormalitiesTime frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • Pinnacle Oncology Hematology

    Scottsdale, Arizona

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • San Diego Pacific Oncology and Hematology Associates, Inc.

    Encinitas, California

  • University of Southern California (USC)

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • UCLA Medical Center

    Santa Monica, California

  • Florida Cancer Specialists

    Sarasota, Florida

  • Parkview Research Center

    Fort Wayne, Indiana

  • Indiana University Health Goshen Center for Cancer Care

    Goshen, Indiana

  • Washington University School of Medicine

    St Louis, Missouri

  • Cornell University

    New York, New York

  • Greenville Health System, Institute for Translational Oncology Research

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt

    Nashville, Tennessee

  • UT Southwestern

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • Northwest Medical Specialties

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.